Press Releases

Press Releases

Press Releases

June 29, 2016
People affected by FCS invited to share their experience   CAMBRIDGE, Mass., June 29, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing drugs to treat patients with
June 27, 2016
CAMBRIDGE, Mass., June 27, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly owned  subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the publication in  Diabetes Care  of positive clinical data from a Phase 2 study of volanesorsen in
May 16, 2016
Study designed to support regulatory filings in U.S., E.U. and Canada for volanesorsen   CAMBRIDGE, Mass., May 16, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing innovative
April 6, 2016
CAMBRIDGE, Mass., April 6, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced that management will present a
March 31, 2016
CAMBRIDGE, Mass., March 31, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, recognizes World Lipodystrophy Day and has partnered with
March 4, 2016
CAMBRIDGE, Mass., March 4, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced that management will present a
January 19, 2016
Appointment adds depth in clinical and regulatory leadership CAMBRIDGE, Mass., Jan. 19, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases,
November 8, 2015
Webcast to review data scheduled for Sunday, November 8 at 1:00 p.m. Eastern Time CARLSBAD, Calif., and CAMBRIDGE, Mass., Nov. 8, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), and its subsidiary, Akcea Therapeutics, today announced positive results from a
November 5, 2015
Trial marks second study for volanesorsen in a rare, genetic lipid disorder CARLSBAD, Calif., and CAMBRIDGE, Mass., Nov. 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) and its wholly owned subsidiary, Akcea Therapeutics, today announced the start of a Phase 3 study to evaluate
July 29, 2015
Publication highlights the therapeutic potential of volanesorsen to address unmet needs in patients with high apoC-III and triglyceride levels CARLSBAD, Calif. and CAMBRIDGE, Mass. , July 29, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics,